Stocktoria
OCULAR THERAPEUTIX, INC OCUL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-07-25
OCULAR THERAPEUTIX, INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $52.0M | $63.7M | $58.4M | $51.5M | $43.5M |
| R&D expense | $197.1M | $127.6M | $61.1M | $53.5M | $50.1M |
| Operating income | -$270.0M | -$171.8M | -$82.4M | -$78.7M | -$78.0M |
| Interest expense | — | — | $11.3M | $7.0M | $6.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$265.9M | -$193.5M | -$80.7M | -$71.0M | -$6.6M |
| EPS (diluted) | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 |
| Operating cash flow | -$204.9M | -$134.7M | -$70.2M | -$59.6M | -$65.5M |
| Free cash flow | -$216.9M | -$136.0M | -$76.3M | -$63.3M | -$66.7M |
| Cash & equivalents | $737.1M | $392.1M | $195.8M | $102.3M | $164.2M |
| Inventory | $3.6M | $3.0M | $2.3M | $2.0M | $1.2M |
| Total assets | $808.1M | $457.9M | $252.1M | $149.3M | $204.9M |
| Total liabilities | $153.7M | $142.6M | $160.9M | $113.9M | $116.9M |
| Shareholders' equity | $654.3M | $315.3M | $91.1M | $35.4M | $88.0M |
Source: SEC EDGAR filings · CIK 0001393434 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.